Pharmaceuticals, Biotechnology and Life Sciences
BALERNA, Switzerland–(BUSINESS WIRE)–PKU GOLIKE®, the brand new generation of Phenylalanine (PHe)-free medical food for Phenylketonuria (PKU) dietary management, is now…
Preliminary Annual Revenue Increase by 2.7x Compared to Prior Year SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”)…
–Study will test efficacy and safety of novel docetaxel-based oral therapeutic– AMSTERDAM–(BUSINESS WIRE)–Modra Pharmaceuticals B.V. (“Modra”) today announced that the…
OSS, The Netherlands–(BUSINESS WIRE)–Lead Pharma, a pharmaceutical company developing innovative medicines for the treatment of immunological and oncological indications, today…
@alvogenpr subsidiary in Taiwan, Lotus Pharmaceuticals today announced capital and business collaboration agreements with Fuji Pharma in Japan, as Fuji has acquired a 2.0% stake in Lotus for approximately US$20 million (or NT$ 617 million, JPY 2.2 billion). Lotus has also acquired 3.9% stake in Fuji for an equal sum.
Verona Pharma as Non-Executive Director
The new Oasmia board, led by Jörgen Olsson who was elected as the Chairman, independent Board member and former CEO of Hoist Finance, will review the business and proceedings of Oasmia in several aspects.
BOSTON–(BUSINESS WIRE)–Gelesis, a biotechnology company developing first-in-class mechanotherapeutics to treat obesity and other chronic diseases related to the gastrointestinal (GI)…
ALAMEDA, Calif.–(BUSINESS WIRE)–AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company focused on innovative therapeutics for human aging, announced today…
German Merck, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer are dropping the Phase III JAVELIN Ovarian PARP 100 study in which they tested avelumab combined with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, versus an active comparator in treatment-naïve patients with locally advanced or metastatic ovarian cancer (Stage III or Stage IV), as they described in the press release on Wednesday.